| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/03/2023 |
4
| McKew John C. (Chief Scientific Officer) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 1,593 shares
@ $3.28, valued at
$5.2k
Sold 3,407 shares
@ $3.205, valued at
$10.9k
|
|
| 08/03/2023 |
4
| Lawley Lori D (CFO) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 229 shares
@ $3.28, valued at
$751.1 |
|
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
SC 13D/A
| Farb Daniel Stuart reports a 6.1% stake in Lumos Pharma, Inc. |
| 05/25/2023 |
SC 13D/A
| Farb Daniel Stuart reports a 7.9% stake in Lumos Pharma, Inc. |
| 05/12/2023 |
4
| Zoth Lota S. (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/12/2023 |
4
| van Es-Johansson An (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/12/2023 |
4
| Raffin Thomas A. (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/12/2023 |
4
| McCracken Joseph S (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/12/2023 |
4
| LALANDE KEVIN M. (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/12/2023 |
4
| JOHNSON CHAD ALLEN (Director) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Granted 3,345 options to buy
@ $3.42, valued at
$11.4k
|
|
| 05/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/04/2023 |
4
| POWERS BRADLEY J (General Counsel) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 342 shares
@ $3.31, valued at
$1.1k
|
|
| 04/04/2023 |
4
| McKew John C. (Chief Scientific Officer) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 1,036 shares
@ $3.31, valued at
$3.4k
Sold 2,214 shares
@ $3.27, valued at
$7.2k
|
|
| 04/04/2023 |
4
| Lawley Lori D (CFO) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 274 shares
@ $3.31, valued at
$906.9 |
|
| 04/04/2023 |
4
| Hawkins Richard J (CEO) has filed a Form 4 on LUMOS PHARMA, INC.|
Txns:
| Paid exercise price by delivering 1,522 shares
@ $3.31, valued at
$5k
|
|
| 04/03/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/01/2023 |
8-K
| Investor presentation, Quarterly results |
| 02/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|